Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Dec 10, 2021 12:03pm
151 Views
Post# 34218932

RE:Nash tag conference

RE:Nash tag conference Well, for starters, it is more accurately described as phase III ready than just phase III. Then you have the history of the program, which is unconventional to say the least and needed several miracles to occur to get to the point of being phase III ready. But while we celebrate the incredible job the company did toy get to this point, most observers look at their phase III NASH asset and don't know what to make of it. So, TH's NASH prgram is the black sheep of the NASH drug industry and will likely remain so until they have positive data on the first 400 patients. 

Bucknelly21 wrote: How can a phase 3 Nash company like Thtx get lost in the mix of 2-3 others?!? They apparently are going to a Nash tag conference in Utah and aren't even presenting? They have a booth lol so embarrassing how much they botched the Nash opportunity 


<< Previous
Bullboard Posts
Next >>